data-recordsHuman Longevity, Inc. (HLI), the genomics-based, technology driven company working to revolutionize the practice of medicine, has announced a 10 year deal with AstraZeneca to sequence and analyse up to 500,000 DNA samples from AstraZeneca clinical trials.

The genomic insights from the collaboration will be added to the HLI Knowledgebase, building upon what is already the most comprehensive database of its kind. The deal was announced at a press conference with AstraZeneca in Cambridge, UK. Financial terms of the deal were not disclosed.

AstraZeneca will share up to 500,000 DNA samples with Human Longevity, collected under optional informed consent in AstraZenenca’s clinical trials during the course of the collaboration. HLI will sequence the genomes from these samples and from future samples donated during the next 10 years by patients in AstraZeneca’s trials.

These data will be shared with AstraZeneca who will also gain access to HLI’s unique database, the HLI Knowledgebase, which is slated to have up to 1 million integrated health records with genome, molecular and clinical data by 2020. AstraZeneca will work with HLI’s world-leading machine learning, pattern recognition and analytical techniques to interpret the genomic data.

“We are excited to establish this long-term relationship with AstraZeneca, who are now establishing themselves as a leader in genomic-focused research,” said J. Craig Venter, PhD, co-founder and CEO, HLI. “We look forward to working together to use HLI’s proprietary computational methods and genomic data insights to better inform clinical trials and drug development.”

The HLI Knowledgebase, which was recently awarded a 2016 Bio-IT World Best Practice Award, is a key tool in the company’s portfolio to transform how medicine is practiced. The Knowledgebase contains tens of thousands of high-quality samples with genomic and phenotypic data and can be used to help customers streamline drug development, aid in discovery of biomarker and companion diagnostics, and rescue and repurpose drugs from failed clinical trials.